# US 2002/0160984 A1 · Fused tricyclic compounds, methods and compositions for inhibiting parp activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0160984 A1
- Document ID: US20020160984A1
- Status: Published application
- Kind: A1
- Application number: 10/109,645
- Filed: 2002-04-01
- Published: 2002-10-31
- Earliest claimed: 1998-05-15
- Assignees: Guilford Pharmaceuticals Inc.
- Inventors: Jia-He Li; Jie Zhang
- Web page: https://patentgrep.com/patent/US20020160984A1

## CPC

- C07D 221/14: Aza-phenalenes, e.g. 1,8-naphthalimide
- A61K 41/0038: {Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy (radiotherapy per se A61N5/10)}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A compound of formula I: 1 or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein the compound of formula I is present in an amount that is effective for treating diabetes; and wherein: Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, carbocyclic or heterocyclic ring, wherein Y and any heteroatom(s) therein is unsubstituted or independently substituted with at least one non-interfering hydroxy, amino, nitro, dimethylamino, alkylamino, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl substituent; R1 and R3 are independently hydrogen, alkyl, halo, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, —COOR5, or a moiety selected from the group consisting of: 2 wherein R7 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl; R2, when present, is hydrogen, alkyl, alkenyl, amino, cycloalkyl, cycloalkenyl, aralkyl or aryl; R4, R5 and R6 are independently hydrogen, hydroxy, amino, dimethylamino, alkylamino, nitro, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl; wherein R2, R4, R5 and R6 are unsubstituted or independently substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkoxy, phenoxy, benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, dimethylamino, alkylamino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, alkylthio, sulfhydryl, halo, haloalkyl, trifluoromethyl and aryl.

## Claims

### Claim 1

A compound of formula I:
42
or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:
Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, carbocyclic or heterocyclic ring, wherein Y and any heteroatom(s) therein is unsubstituted or independently substituted with at least one non-interfering hydroxy, amino, nitro, dimethylamino, alkylamino, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl substituent;
R1 and R3 are independently hydrogen, alkyl, halo, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, —COOR5, or a moiety selected from the group consisting of:
43
wherein:
R7 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R2, when present, is hydrogen, alkyl, alkenyl, amino, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R4, R5 and R6 are independently hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
wherein R2, R4, R5 and R6 are unsubstituted or independently substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkoxy, phenoxy, benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, dimethylamino, alkylamino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, alkylthio, sulfhydryl, halo, haloalkyl, trifluoromethyl and aryl; provided that
(i) when R1, R2, R4, R5 and R6 are each hydrogen and Y is a 5-membered, unsaturated, heterocyclic ring containing a nitrogen as its sole heteroatom, R3 is not double bonded oxygen;
(ii) when R1, R4, R5 and R6 are each hydrogen, R2 is hydrogen or lower alkyl, and Y is a 5-membered, unsaturated, heterocyclic ring containing a nitrogen as its sole heteroatom, R3 is not hydrogen;
(iii) when R4, R5 and R6 are each hydrogen, R2 is hydrogen or lower alkyl, R3 is hydrogen, lower alkyl or phenyl, and Y is a 6-membered, non-aromatic, heterocyclic ring containing a nitrogen as its sole heteroatom, R1 is not hydrogen;
(iv) when R2 is alkyl or aryl, R3 is double bonded oxygen, and Y is a 6-membered, carbocyclic, unsaturated ring, R1 is not double bonded oxygen;
(v) when R1, R3, R4, R5 and R6 are each hydrogen, and Y forms a five-membered N-containing ring, then R2 is not hydrogen or alkyl; and
(vi) when R2, R4, R5 and R6 are each hydrogen, and Y is phenyl, then both R1 and R3 cannot be double bonded oxygen.

### Claim 2 (depends on 1)

The compound of claim 1, wherein Y has at least one site of unsaturation.

### Claim 3 (depends on 1)

The compound of claim 1, wherein Y represents the atoms necessary to form a fused benzene ring.

### Claim 4 (depends on 1)

The compound of claim 1, wherein Y represents the atoms necessary to form a 5- to 6-membered carbocyclic ring.

### Claim 5 (depends on 4)

The compound of claim 4, wherein Y is aromatic.

### Claim 6 (depends on 4)

The compound of claim 4, wherein Y is non-aromatic.

### Claim 7 (depends on 1)

The compound of claim 1, wherein Y represents the atoms necessary to form a 5- to 6-membered N-containing ring.

### Claim 8 (depends on 7)

The compound of claim 7, wherein Y is aromatic.

### Claim 9 (depends on 7)

The compound of claim 7, wherein Y is non-aromatic.

### Claim 10 (depends on 7)

The compound of claim 7, wherein the compound is selected from the group consisting of:
44

### Claim 11 (depends on 10)

The compound of claim 10, wherein the compound is
45

### Claim 12 (depends on 1)

The compound of claim 1, wherein said compound has an IC50 of 100 uM or lower for inhibiting poly(ADP-ribose) polymerase in vitro.

### Claim 13 (depends on 1)

The compound of claim 1, wherein said compound has an IC50 of 25 uM or lower for inhibiting poly(ADP-ribose) polymerase in vitro.

### Claim 14

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I:
46
or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:
Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, carbocyclic or heterocyclic ring, wherein Y and any heteroatom(s) therein is unsubstituted or independently substituted with at least one non-interfering hydroxy, amino, nitro, dimethylamino, alkylamino, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl substituent;
R1 and R3 are independently hydrogen, alkyl, halo, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, —COOR5, or a moiety selected from the group consisting of:
47
wherein R7 is alkyl, alkenyl, cycloalkyl, cyclo-alkenyl, aralkyl or aryl;
R2, when present, is hydrogen, alkyl, alkenyl, amino, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R4, R5 and R6 are independently hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
wherein R2, R4, R5 and R6 are unsubstituted or independently substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkoxy, phenoxy, benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, dimethylamino, alkylamino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, alkylthio, sulfhydryl, halo, haloalkyl, trifluoromethyl and aryl.

### Claim 15 (depends on 14)

The composition of claim 14, wherein Y has at least one site of unsaturation.

### Claim 16 (depends on 14)

The composition of claim 14, wherein Y represents the atoms necessary to form a benzene ring.

### Claim 17 (depends on 14)

The composition of claim 14, wherein Y represents the atoms necessary to form a 5- to 6-membered carbocyclic ring.

### Claim 18 (depends on 17)

The composition of claim 17, wherein Y is aromatic.

### Claim 19 (depends on 17)

The composition of claim 17, wherein Y is non-aromatic.

### Claim 20 (depends on 14)

The composition of claim 14, wherein Y represents the atoms necessary to form a 5- to 6-membered N-containing ring.

### Claim 21 (depends on 20)

The composition of claim 20, wherein Y is aromatic.

### Claim 22 (depends on 20)

The composition of claim 20, wherein Y is non-aromatic.

### Claim 23 (depends on 14)

The composition of claim 14, wherein the compound is selected from the group consisting of:
48

### Claim 24 (depends on 23)

The composition of claim 23, wherein the compound is
49

### Claim 25 (depends on 14)

The composition of claim 14, wherein said compound has an IC50 of 100 uM or lower for inhibiting poly(ADP-ribose) polymerase in vitro.

### Claim 26 (depends on 14)

The composition of claim 14, wherein said compound has an IC50 of 25 uM or lower for inhibiting poly(ADP-ribose) polymerase in vitro.

### Claim 27 (depends on 14)

The composition of claim 14, wherein said composition is administered as a sterile solution, suspension or emulsion, in a single or divided dose.

### Claim 28 (depends on 14)

The composition of claim 14, wherein said composition is administered as a capsule or tablet containing a single or divided dose of said compound.

### Claim 29 (depends on 14)

The composition of claim 14, wherein the carrier comprises a biodegradable polymer.

### Claim 30 (depends on 29)

The composition of claim 29, wherein the composition is a solid implant.

### Claim 31 (depends on 29)

The composition of claim 29, wherein the biodegradable polymer releases the compound of formula I over a prolonged period of time.

### Claim 32

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I:
50
or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein the compound of formula I is present in an amount that is effective for inhibiting PARP activity; and wherein:
Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, carbocyclic or heterocyclic ring, wherein Y and any heteroatom(s) therein is unsubstituted or independently substituted with at least one non-interfering hydroxy, amino, nitro, dimethylamino, alkylamino, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl substituent;
R1 and R3 are independently hydrogen, alkyl, halo, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, —COOR5, or a moiety selected from the group consisting of:
51
wherein R7 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R2, when present, is hydrogen, alkyl, alkenyl, amino, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R4, R5 and R6 are independently hydrogen, hydroxy, amino, dimethylamino, alkylamino, nitro, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
wherein R2, R4, R5 and R6 are unsubstituted or independently substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkoxy, phenoxy, benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, dimethylamino, alkylamino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, alkylthio, sulfhydryl, halo, haloalkyl, trifluoromethyl and aryl.

### Claim 33 (depends on 32)

The composition of claim 32, wherein the compound is selected from the group consisting of:
52

### Claim 34 (depends on 33)

The composition of claim 33, wherein the compound is
53

### Claim 35 (depends on 32)

The pharmaceutical composition of claim 32 for treatment or prevention of diseases or conditions selected from the group consisting of tissue damage resulting from cell damage or death due to necrosis or apoptosis, neuronal mediated tissue damage or diseases, neural tissue damage resulting from ischemia and reperfusion injury, neurological disorders and neurodegenerative diseases, vascular stroke, cardiovascular disorders, age-related macular degeneration, AIDS and other immune senescence diseases, arthritis, atherosclerosis, cachexia, cancer, degenerative diseases of skeletal muscle involving replicative senescence, diabetes, head trauma, immune senescence, inflammatory bowel disorders, muscular dystrophy, osteoarthritis, osteoporosis, chronic pain, acute pain, neuropathic pain, nervous insult, peripheral nerve injury, renal failure, retinal ischemia, septic shock, and skin aging, diseases or disorders relating to lifespan or proliferative capacity of cells, and diseases or disease conditions induced or exacerbated by cellular senescence.

### Claim 36

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I:
54
or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein the compound of formula I is present in an amount that is effective for effecting a neuronal activity not mediated by NMDA toxicity; and wherein:
Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, carbocyclic or heterocyclic ring, wherein Y and any heteroatom(s) therein is unsubstituted or independently substituted with at least one non-interfering hydroxy, amino, nitro, dimethylamino, alkylamino, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl substituent;
R1 and R3 are independently hydrogen, alkyl, halo, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, —COOR5 or a moiety selected from the group consisting of:
55
wherein R7 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R2, when present, is hydrogen, alkyl, alkenyl, amino, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R4, R5 and R6 are independently hydrogen, hydroxy, amino, dimethylamino, alkylamino, nitro, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
wherein R2, R4, R5 and R6 are unsubstituted or independently substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkoxy, phenoxy, benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, dimethylamino, alkylamino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo., diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, alkylthio, sulfhydryl, halo, haloalkyl, trifluoromethyl and aryl.

### Claim 37 (depends on 36)

The composition of claim 36, wherein the neuronal activity is selected from the group consisting of stimulation of damaged neurons, promotion of neuronal regeneration, prevention of neurodegeneration, and treatment of a neurological disorder.

### Claim 38 (depends on 36)

The composition of claim 36, wherein said damaged neurons result from cerebral ischemia or reperfusion injury.

### Claim 39 (depends on 36)

The composition of claim 36, wherein the neurological disorder is selected from the group consisting of peripheral neuropathy caused by physical injury or disease state, traumatic brain injury, physical damage to the spinal cord, stroke associated with brain damage, demyelinating disease and neurological disorder relating to neurodegeneration.

### Claim 40 (depends on 39)

The composition of claim 39, wherein the neurological disorder relating to neurodegeneration is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease and amyotrophic lateral sclerosis.

### Claim 41 (depends on 36)

The composition of claim 36, wherein the compound is selected from the group consisting of
56

### Claim 42 (depends on 41)

The composition of claim 41, wherein the compound is
57

### Claim 43

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I:
58
or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein the compound of formula I is present in an amount that is effective for treating arthritis; and wherein:
Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, carbocyclic or heterocyclic ring, wherein Y and any heteroatom(s) therein is unsubstituted or independently substituted with at least one non-interfering hydroxy, amino, nitro, dimethylamino, alkylamino, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl substituent;
R1 and R3 are independently hydrogen, alkyl, halo, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, —COOR5, or a moiety selected from the group consisting of:
59
wherein R7 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R2, when present, is hydrogen, alkyl, alkenyl, amino, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R4, R5 and R6 are independently hydrogen, hydroxy, amino, dimethylamino, alkylamino, nitro, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
wherein R2, R4, R5 and R6 are unsubstituted or independently substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkoxy, phenoxy, benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, dimethylamino, alkylamino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, alkylthio, sulfhydryl, halo, haloalkyl, trifluoromethyl and aryl.

### Claim 44 (depends on 43)

The composition of claim 43, wherein the compound is selected from the group consisting of:
60

### Claim 45 (depends on 44)

The composition of claim 44, wherein the compound is
61

### Claim 46

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I:
62
or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein the compound of formula I is present in an amount that is effective for treating diabetes; and wherein:
Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, carbocyclic or heterocyclic ring, wherein Y and any heteroatom(s) therein is unsubstituted or independently substituted with at least one non-interfering hydroxy, amino, nitro, dimethylamino, alkylamino, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl substituent;
R1 and R3 are independently hydrogen, alkyl, halo, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, —COOR5, or a moiety selected from the group consisting of:
63
wherein R7 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R2, when present, is hydrogen, alkyl, alkenyl, amino, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R4, R5 and R6 are independently hydrogen, hydroxy, amino, dimethylamino, alkylamino, nitro, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
wherein R2, R4, R5 and R6 are unsubstituted or independently substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkoxy, phenoxy, benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, dimethylamino, alkylamino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, alkylthio, sulfhydryl, halo, haloalkyl, trifluoromethyl and aryl.

### Claim 47 (depends on 46)

The composition of claim 46, wherein the compound is selected from the group consisting of:
64

### Claim 48 (depends on 47)

The composition of claim 47, wherein the compound is
65

### Claim 49

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I:
66
or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein the compound of formula I is present in an amount that is effective for treating an inflammatory bowel disorder; and wherein:
Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, carbocyclic or heterocyclic ring, wherein Y and any heteroatom(s) therein is unsubstituted or independently substituted with at least one non-interfering hydroxy, amino, nitro, dimethylamino, alkylamino, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl substituent;
R1 and R3 are independently hydrogen, alkyl, halo, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, —COOR5, or a moiety selected from the group consisting of:
67
wherein R7 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R2, when present, is hydrogen, alkyl, alkenyl, amino, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R4, R5 and R6 are independently hydrogen, hydroxy, amino, dimethylamino, alkylamino, nitro, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
wherein R2, R4, R5 and R6 are unsubstituted or independently substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkoxy, phenoxy, benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, dimethylamino, alkylamino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, alkylthio, sulfhydryl, halo, haloalkyl, trifluoromethyl and aryl.

### Claim 50 (depends on 49)

The composition of claim 49, wherein the bowel disorder is colitis.

### Claim 51 (depends on 49)

The composition of claim 49, wherein the bowel disorder is Crohn's disease.

### Claim 52 (depends on 49)

The composition of claim 49, wherein the compound is selected from the group consisting of:
68

### Claim 53 (depends on 52)

The composition of claim 52, wherein the compound is
69

### Claim 54

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I:
70
or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein the compound of formula I is present in an amount that is effective for treating a cardiovascular disorder; and wherein:
Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, carbocyclic or heterocyclic ring, wherein Y and any heteroatom(s) therein is unsubstituted or independently substituted with at least one non-interfering hydroxy, amino, nitro, dimethylamino, alkylamino, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl substituent;
R1 and R3 are independently hydrogen, alkyl, halo, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, —COOR5 or a moiety selected from the group consisting of:
71
wherein R7 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R2, when present, is hydrogen, alkyl, alkenyl, amino, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R4, R5 and R6 are independently hydrogen, hydroxy, amino, dimethylamino, alkylamino, nitro, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
wherein R2, R4, R5 and R6 are unsubstituted or independently substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkoxy, phenoxy, benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, dimethylamino, alkylamino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, alkylthio, sulfhydryl, halo, haloalkyl, trifluoromethyl and aryl.

### Claim 55 (depends on 54)

The composition of claim 54, wherein the cardiovascular disorder is selected from the group consisting of cardiovascular tissue damage, coronary artery disease, myocardial infarction, angina pectoris and cardiogenic shock.

### Claim 56 (depends on 54)

The composition of claim 54, wherein the compound is selected from the group consisting of:
72

### Claim 57 (depends on 56)

The composition of claim 56, wherein the compound is
73

### Claim 58

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I:
74
or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein the compound of formula I is present in an amount that is effective for treating septic shock; and wherein:
Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, carbocyclic or heterocyclic ring, wherein Y and any heteroatom(s) therein is unsubstituted or independently substituted with at least one non-interfering hydroxy, amino, nitro, dimethylamino, alkylamino, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl substituent;
R1 and R3 are independently hydrogen, alkyl, halo, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, —COOR5, or a moiety selected from the group consisting of:
75
wherein R7 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R2, when present, is hydrogen, alkyl, alkenyl, amino, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R4, R5 and R6 are independently hydrogen, hydroxy, amino, dimethylamino, alkylamino, nitro, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
wherein R2, R4, R5 and R6 are unsubstituted or independently substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkoxy, phenoxy, benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, dimethylamino, alkylamino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, alkylthio, sulfhydryl, halo, haloalkyl, trifluoromethyl and aryl.

### Claim 59 (depends on 58)

The composition of claim 58, wherein the type of septic shock is endotoxic shock.

### Claim 60 (depends on 58)

The composition of claim 58, wherein the compound is selected from the group consisting of:
76

### Claim 61 (depends on 60)

The composition of claim 60, wherein the compound
77

### Claim 62

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I:
78
or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein the compound of formula I is present in an amount that is effective for treating cancer; and wherein:
Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, carbocyclic or heterocyclic ring, wherein Y and any heteroatom(s) therein is unsubstituted or independently substituted with at least one non-interfering hydroxy, amino, nitro, dimethylamino, alkylamino, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl substituent;
R1 and R3 are independently hydrogen, alkyl, halo, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, —COOR5, or a moiety selected from the group consisting of:
79
wherein R7 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R2, when present, is hydrogen, alkyl, alkenyl, amino, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R4, R5 and R6 are independently hydrogen, hydroxy, amino, dimethylamino, alkylamino, nitro, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
wherein R2, R4, R5 and R6 are unsubstituted or independently substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkoxy, phenoxy, benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, dimethylamino, alkylamino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, alkylthio, sulfhydryl, halo, haloalkyl, trifluoromethyl and aryl.

### Claim 63 (depends on 62)

The composition of claim 62, wherein the cancer is selected from the group consisting of ACTH-producing tumors, acute lymphocytic leukemia, acute nonlymphocytic leukemia, cancer of the adrenal cortex, bladder cancer, brain cancer, breast cancer, cervical cancer, chronic lymphocytic leukemia, chronic myelocytic leukemia, colorectal cancer, cutaneous T-cell lymphoma, endometrial cancer, esophageal cancer, Ewing's sarcoma, gallbladder cancer, hairy cell leukemia, head & neck cancer, Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer, liver cancer, lung cancer (small and/or non-small cell), malignant peritoneal effusion, malignant pleural effusion, melanoma, mesothelioma, multiple myeloma, neuroblastoma, non-Hodgkin's lymphoma, osteosarcoma, ovarian cancer, ovary (germ cell) cancer, prostate cancer, pancreatic cancer, penile cancer, retinoblastoma, skin cancer, soft-tissue sarcoma, squamous cell carcinomas, stomach cancer, testicular cancer, thyroid cancer, trophoblastic neoplasms, uterine cancer, vaginal cancer, cancer of the vulva and Wilm's tumor.

### Claim 64 (depends on 62)

The composition of claim 62, wherein the compound is selected from the group consisting of:
80

### Claim 65 (depends on 62)

The composition of claim 62, wherein the compound is
81

### Claim 66 (depends on 65)

The composition of claim 65, wherein the carrier comprises a biodegradable polymer.

### Claim 67 (depends on 66)

The composition of claim 66, wherein the composition is a solid implant.

### Claim 68 (depends on 66)

The composition of claim 66, wherein the biodegradable polymer releases the compound of formula I over a prolonged period of time.

### Claim 69

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I:
82
or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein the compound of formula I is present in an amount that is effective for radiosensitizing tumor cells; and wherein:
Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, carbocyclic or heterocyclic ring, wherein Y and any heteroatom(s) therein is unsubstituted or independently substituted with at least one non-interfering hydroxy, amino, nitro, dimethylamino, alkylamino, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl substituent;
R1 and R3 are independently hydrogen, alkyl, halo, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, —COOR5, or a moiety selected from the group consisting of:
83
wherein R7 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R2, when present, is hydrogen, alkyl, alkenyl, amino, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R4, R5 and R6 are independently hydrogen, hydroxy, amino, dimethylamino, alkylamino, nitro, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
wherein R2, R4, R5 and R6 are unsubstituted or independently substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkoxy, phenoxy, benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, dimethylamino, alkylamino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, alkylthio, sulfhydryl, halo, haloalkyl, trifluoromethyl and aryl.

### Claim 70 (depends on 69)

The composition of claim 69, wherein said tumor cells are selected from the group consisting of ACTH-producing tumors, acute lymphocytic leukemia, acute nonlymphocytic leukemia, cancer of the adrenal cortex, bladder cancer, brain cancer, breast cancer, cervical cancer, chronic lymphocytic leukemia, chronic myelocytic leukemia, colorectal cancer, cutaneous T-cell lymphoma, endometrial cancer, esophageal cancer, Ewing's sarcoma, gallbladder cancer, hairy cell leukemia, head & neck cancer, Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer, liver cancer, lung cancer (small and/or non-small cell), malignant peritoneal effusion, malignant pleural effusion, melanoma, mesothelioma, multiple myeloma, neuroblastoma, non-Hodgkin's lymphoma, osteosarcoma, ovarian cancer, ovary (germ cell) cancer, prostate cancer, pancreatic cancer, penile cancer, retinoblastoma, skin cancer, soft-tissue sarcoma, squamous cell carcinomas, stomach cancer, testicular cancer, thyroid cancer, trophoblastic neoplasms, uterine cancer, vaginal cancer, cancer of the vulva and Wilm's tumor.

### Claim 71 (depends on 69)

The composition of claim 69, wherein the compound is selected from the group consisting of:
84

### Claim 72 (depends on 71)

The composition of claim 71, wherein the compound is
85

### Claim 73

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I:
86
or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein the compound of formula I is present in an amount that is effective for expanding or increasing the lifespan or proliferative capacity of cells; and wherein:
Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, carbocyclic or heterocyclic ring, wherein Y and any heteroatom(s) therein is unsubstituted or independently substituted with at least one non-interfering hydroxy, amino, nitro, dimethylamino, alkylamino, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl substituent;
R1 and R3 are independently hydrogen, alkyl, halo, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, —COOR5, or a moiety selected from the group consisting of:
87
wherein R7 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R2, when present, is hydrogen, alkyl, alkenyl, amino, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R4, R5 and R6 are independently hydrogen, hydroxy, amino, dimethylamino, alkylamino, nitro, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
wherein R2, R4, R5 and R6 are unsubstituted or independently substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkoxy, phenoxy, benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, dimethylamino, alkylamino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, alkylthio, sulfhydryl, halo, haloalkyl, trifluoromethyl and aryl.

### Claim 74 (depends on 73)

The composition of claim 73, wherein the compound is selected from the group consisting of:
88

### Claim 75 (depends on 74)

The composition of claim 74, wherein the compound is
89

### Claim 76

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I:
90
or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer or mixtures thereof, wherein the compound of formula I is present in an amount that is effective for altering the gene expression of senescent cells; and wherein:
Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, carbocyclic or heterocyclic ring, wherein Y and any heteroatom(s) therein is unsubstituted or independently substituted with at least one non-interfering hydroxy, amino, nitro, dimethylamino, alkylamino, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl substituent;
R1 and R3 are independently hydrogen, alkyl, halo, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, —COOR5, or a moiety selected from the group consisting of:
91
wherein R7 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R2, when present, is hydrogen, alkyl, alkenyl, amino, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R4, R5 and R6 are independently hydrogen, hydroxy, amino, dimethylamino, alkylamino, nitro, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
wherein R2, R4, R5 and R6 are unsubstituted or independently substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkoxy, phenoxy, benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, dimethylamino, alkylamino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, alkylthio, sulfhydryl, halo, haloalkyl, trifluoromethyl and aryl.

### Claim 77 (depends on 76)

The composition of claim 76, wherein the compound is selected from the group consisting of:
92

### Claim 78 (depends on 77)

The composition of claim 77, wherein the compound is
93

### Claim 79

A method of inhibiting PARP activity comprising administering a compound of formula I:
94
or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:
Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, carbocyclic or heterocyclic ring, wherein Y and any heteroatom(s) therein is unsubstituted or independently substituted with at least one non-interfering hydroxy, amino, nitro, dimethylamino, alkylamino, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl substituent;
R1 and R3 are independently hydrogen, alkyl, halo, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, —COOR5, or a moiety selected from the group consisting of:
95
wherein R7 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R2, when present, is hydrogen, alkyl, alkenyl, amino, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R4, R5 and R6 are independently hydrogen, hydroxy, amino, dimethylamino, alkylamino, nitro, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
wherein R2, R4, R5 and R6 are unsubstituted or independently substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkoxy, phenoxy, benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, dimethylamino, alkylamino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, alkylthio, sulfhydryl, halo, haloalkyl, trifluoromethyl and aryl.

### Claim 80 (depends on 79)

The method of claim 79, wherein Y has at least one site of unsaturation.

### Claim 81 (depends on 79)

The method of claim 79, wherein Y represents the atoms necessary to form a fused benzene ring.

### Claim 82 (depends on 79)

The method of claim 79, wherein Y represents the atoms necessary to form a 5- to 6-membered carbocyclic ring.

### Claim 83 (depends on 82)

The method of claim 82, wherein Y is aromatic.

### Claim 84 (depends on 82)

The method of claim 82, wherein Y is non-aromatic.

### Claim 85 (depends on 79)

The method of claim 79, wherein Y represents the atoms necessary to form a 5- to 6-membered N-containing heterocyclic ring.

### Claim 86 (depends on 85)

The method of claim 85, wherein Y is aromatic.

### Claim 87 (depends on 85)

The method of claim 85, wherein Y is non-aromatic.

### Claim 88 (depends on 79)

The method of claim 79, wherein the compound is elected from the group consisting of:
96

### Claim 89 (depends on 88)

The method of claim 88, wherein the compound is
97

### Claim 90 (depends on 79)

The method of claim 79, wherein said compound has an IC50 of 100 uM or lower for inhibiting poly(ADP-ribose) polymerase in vitro.

### Claim 91 (depends on 79)

The method of claim 79, wherein said compound has an IC50 of 25 uM or lower for inhibiting poly(ADP-ribose) polymerase in vitro.

### Claim 92 (depends on 79)

The method of claim 79 further comprising treating or preventing diseases or conditions selected from the group consisting of tissue damage resulting from cell damage or death due to necrosis or apoptosis, neuronal mediated tissue damage or diseases, neural tissue damage resulting from ischemia and reperfusion injury, neurological disorders and neurodegenerative diseases, vascular stroke, cardiovascular disorders, age-related macular degeneration, AIDS and other immune senescence diseases, arthritis, atherosclerosis, cachexia, cancer, degenerative diseases of skeletal muscle involving replicative senescence, diabetes, head trauma, immune senescence, inflammatory bowel disorders, muscular dystrophy, Qsteoarthritis, osteoporosis, chronic pain, acute pain, neuropathic pain, nervous insult, peripheral nerve injury, renal failure, retinal ischemia, septic shock, and skin aging, diseases or disorders relating to lifespan or proliferative capacity of cells, and diseases or disease conditions induced or exacerbated by cellular senescence.

### Claim 93

A method of effecting a neuronal activity not mediated by NMDA toxicity in an animal comprising administering to said animal an effective amount of a compound of formula I:
98
or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:
Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, carbocyclic or heterocyclic ring, wherein Y and any heteroatom(s) therein is unsubstituted or independently substituted with at least one non-interfering hydroxy, amino, nitro, dimethylamino, alkylamino, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl substituent;
R1 and R3 are independently hydrogen, alkyl, halo, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, —COOR5, or a moiety selected from the group consisting of:
99
wherein R7 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R2, when present, is hydrogen, alkyl, alkenyl, amino, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R4, R5 and R6 are independently hydrogen, hydroxy, amino, dimethylamino, alkylamino, nitro, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
wherein R2, R4, R5 and R6 are unsubstituted or independently substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkoxy, phenoxy, benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, dimethylamino, alkylamino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, alkylthio, sulfhydryl, halo, haloalkyl, trifluoromethyl and aryl.

### Claim 94 (depends on 93)

The method of claim 93, wherein the neuronal activity is selected from the group consisting of stimulation of damaged neurons, promotion of neuronal regeneration, prevention of neurodegeneration, and treatment of a neurological disorder.

### Claim 95 (depends on 94)

The method of claim 94, wherein said damaged neurons result from cerebral ischemia or reperfusion injury.

### Claim 96 (depends on 94)

The method of claim 94, wherein the neurological disorder is selected from the group consisting of peripheral neuropathy caused by physical injury or disease state, traumatic brain injury, physical damage to the spinal cord, stroke associated with brain damage, demyelinating disease and neurological disorder relating to neurodegeneration.

### Claim 97 (depends on 96)

The method of claim 96, wherein the neurological disorder relating to neurodegeneration is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease and amyotrophic lateral sclerosis.

### Claim 98 (depends on 93)

The method of claim 93, wherein the compound is selected from the group consisting of:
100

### Claim 99 (depends on 98)

The method of claim 98, wherein the compound is
101

### Claim 100

A method of treating arthritis in an animal comprising administering to said animal an effective amount of a compound of formula I:
102
or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:
Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, carbocyclic or heterocyclic ring, wherein Y and any heteroatom(s) therein is unsubstituted or independently substituted with at least one non-interfering hydroxy, amino, nitro, dimethylamino, alkylamino, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl substituent;
R1 and R3 are independently hydrogen, alkyl, halo, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, —COOR5, or a moiety selected from the group consisting of:
103
wherein R7 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R2, when present, is hydrogen, alkyl, alkenyl, amino, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R4, R5 and R6 are independently hydrogen, hydroxy, amino, dimethylamino, alkylamino, nitro, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
wherein R2, R4, R5 and R6 are unsubstituted or independently substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkoxy, phenoxy, benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, dimethylamino, alkylamino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, alkylthio, sulfhydryl, halo, haloalkyl, trifluoromethyl and aryl.

### Claim 101 (depends on 100)

The method of claim 100, wherein the compound is selected from the group consisting of:
104

### Claim 102 (depends on 101)

The method of claim 101, wherein the compound is
105

### Claim 103

A method of treating diabetes in an animal comprising administering to said animal an effective amount of a compound of formula I:
106
or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:
Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, carbocyclic or heterocyclic ring, wherein Y and any heteroatom(s) therein is unsubstituted or independently substituted with at least one non-interfering hydroxy, amino, nitro, dimethylamino, alkylamino, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl substituent;
R1 and R3 are independently hydrogen, alkyl, halo, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, —COOR5, or a moiety selected from the group consisting of:
107
wherein R7 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R2, when present, is hydrogen, alkyl, alkenyl, amino, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R4, R5 and R6 are independently hydrogen, hydroxy, amino, dimethylamino, alkylamino, nitro, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
wherein R2, R4, R5 and R6 are unsubstituted or independently substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkoxy, phenoxy, benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, dimethylamino, alkylamino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, alkylthio, sulfhydryl, halo, haloalkyl, trifluoromethyl and aryl.

### Claim 104 (depends on 103)

The method of claim 103, wherein the compound is selected from the group consisting of:
108

### Claim 105 (depends on 104)

The method of claim 104, wherein the compound is
109

### Claim 106

A method of treating an inflammatory bowel disorder in an animal comprising administering to said animal an effective amount of a compound of formula I:
110
or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:
Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, carbocyclic or heterocyclic ring, wherein Y and any heteroatom(s) therein is unsubstituted or independently substituted with at least one non-interfering hydroxy, amino, nitro, dimethylamino, alkylamino, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl substituent;
R1 and R3 are independently hydrogen, alkyl, halo, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, —COOR5, or a moiety selected from the group consisting of:
111
wherein R7 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R2, when present, is hydrogen, alkyl, alkenyl, amino, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R4, R5 and R6 are independently hydrogen, hydroxy, amino, dimethylamino, alkylamino, nitro, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
wherein R2, R4, R5 and R6 are unsubstituted or independently substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkoxy, phenoxy, benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, dimethylamino, alkylamino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, alkylthio, sulfhydryl, halo, haloalkyl, trifluoromethyl and aryl.

### Claim 107 (depends on 106)

The method of claim 106, wherein the bowel disorder is colitis.

### Claim 108 (depends on 106)

The method of claim 106, wherein the bowel disorder is Crohn's disease.

### Claim 109 (depends on 106)

The method of claim 106, wherein the compound is selected from the group consisting of:
112

### Claim 110 (depends on 109)

The method of claim 109, wherein the compound is
113

### Claim 111

A method of treating a cardiovascular in an animal comprising administering to said animal an effective amount of a compound of formula I:
114
or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:
Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, carbocyclic or heterocyclic ring, wherein Y and any heteroatom(s) therein is unsubstituted or independently substituted with at least one non-interfering hydroxy, amino, nitro, dimethylamino, alkylamino, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl substituent;
R1 and R3 are independently hydrogen, alkyl, halo, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, —COOR5, or a moiety selected from the group consisting of:
115
wherein R7 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R2, when present, is hydrogen, alkyl, alkenyl, amino, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R4, R5 and R6 are independently hydrogen, hydroxy, amino, dimethylamino, alkylamino, nitro, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
wherein R2, R4, R5 and R6 are unsubstituted or independently substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkoxy, phenoxy, benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, dimethylamino, alkylamino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, alkylthio, sulfhydryl, halo, haloalkyl, trifluoromethyl and aryl.

### Claim 112 (depends on 111)

The method of claim 111, wherein the cardiovascular disorder is selected from the group consisting of cardiovascular tissue damage, coronary artery disease, myocardial infarction, angina pectoris and cardiogenic shock.

### Claim 113 (depends on 111)

The method of claim 111, wherein the compound is selected from the group consisting of:
116

### Claim 114 (depends on 113)

The method of claim 113, wherein the compound is
117

### Claim 115

A method of treating septic shock in an animal comprising administering to said animal an effective amount of a compound of formula I:
118
or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:
Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, carbocyclic or heterocyclic ring, wherein Y and any heteroatom(s) therein is unsubstituted or independently substituted with at least one non-interfering hydroxy, amino, nitro, dimethylamino, alkylamino, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl substituent;
R1 and R3 are independently hydrogen, alkyl, halo, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, —COOR5, or a moiety selected from the group consisting of:
119
wherein R7 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R2, when present, is hydrogen, alkyl, alkenyl, amino, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R4, R5 and R6 are independently hydrogen, hydroxy, amino, dimethylamino, alkylamino, nitro, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
wherein R2, R4, R5 and R6 are unsubstituted or independently substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkoxy, phenoxy, benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, dimethylamino, alkylamino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, alkylthio, sulfhydryl, halo, haloalkyl, trifluoromethyl and aryl.

### Claim 116 (depends on 115)

The method of claim 115, wherein the type of septic shock is endotoxic shock.

### Claim 117 (depends on 115)

The method of claim 115, wherein the compound is selected from the group consisting of:
120

### Claim 118 (depends on 117)

The method of claim 117, wherein the compound is
121

### Claim 119

A method of treating cancer in an animal comprising administering to said animal an effective amount of a compound of formula I:
122
or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:
Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, carbocyclic or heterocyclic ring, wherein Y and any heteroatom(s) therein is unsubstituted or independently substituted with at least one non-interfering hydroxy, amino, nitro, dimethylamino, alkylamino, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl substituent;
R1 and R3 are independently hydrogen, alkyl, halo, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, —COOR5, or a moiety selected from the group consisting of:
123
wherein R7 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R2, when present, is hydrogen, alkyl, alkenyl, amino, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R4, R5 and R6 are independently hydrogen, hydroxy, amino, dimethylamino, alkylamino, nitro, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
wherein R2, R4, R5 and R6 are unsubstituted or independently substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkoxy, phenoxy, benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, dimethylamino, alkylamino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, alkylthio, sulfhydryl, halo, haloalkyl, trifluoromethyl and aryl.

### Claim 120 (depends on 119)

The method of claim 119, wherein the cancer is selected from the group consisting of ACTH-producing tumors, acute lymphocytic leukemia, acute nonlymphocytic leukemia, cancer of the adrenal cortex, bladder cancer, brain cancer, breast cancer, cervical cancer, chronic lymphocytic leukemia, chronic myelocytic leukemia, colorectal cancer, cutaneous T-cell lymphoma, endometrial cancer, esophageal cancer, Ewing's sarcoma, gallbladder cancer, hairy cell leukemia, head & neck cancer, Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer, liver cancer, lung cancer (small and/or non-small cell), malignant peritoneal effusion, malignant pleural effusion, melanoma, mesothelioma, multiple myeloma, neuroblastoma, non-Hodgkin's lymphoma, osteosarcoma, ovarian cancer, ovary (germ cell) cancer, prostate cancer, pancreatic cancer, penile cancer, retinoblastoma, skin cancer, soft-tissue sarcoma, squamous cell carcinomas, stomach cancer, testicular cancer, thyroid cancer, trophoblastic neoplasms, uterine cancer, vaginal cancer, cancer of the vulva and Wilm's tumor.

### Claim 121 (depends on 119)

The method of claim 119, wherein the compound is selected from the group consisting of:
124

### Claim 122 (depends on 121)

The method of claim 121, wherein the compound is
125

### Claim 123 (depends on 121)

The method of claim 121, wherein the carrier comprises a biodegradable polymer.

### Claim 124 (depends on 123)

The method of claim 123, wherein the composition is a solid implant.

### Claim 125 (depends on 123)

The method of claim 123, wherein the biodegradable polymer releases the compound of formula I over a prolonged period of time.

### Claim 126

A method radiosensitizing tumor cells comprising administering an effective amount of a compound of formula I:
126
or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:
Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, carbocyclic or heterocyclic ring, wherein Y and any heteroatom(s) therein is unsubstituted or independently substituted with at least one non-interfering hydroxy, amino, nitro, dimethylamino, alkylamino, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl substituent;
R1 and R3 are independently hydrogen, alkyl, halo, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, —COOR5, or a moiety selected from the group consisting of:
127
wherein R7 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R2, when present, is hydrogen, alkyl, alkenyl, amino, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R4, R5 and R6 are independently hydrogen, hydroxy, amino, dimethylamino, alkylamino, nitro, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
wherein R2, R4, R5 and R6 are unsubstituted or independently substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkoxy, phenoxy, benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, dimethylamino, alkylamino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, alkylthio, sulfhydryl, halo, haloalkyl, trifluoromethyl and aryl.

### Claim 127 (depends on 126)

The method of claim 126, wherein said tumor cells are selected from the group consisting of ACTH-producing tumors, acute lymphocytic leukemia, acute nonlymphocytic leukemia, cancer of the adrenal cortex, bladder cancer, brain cancer, breast cancer, cervical cancer, chronic lymphocytic leukemia, chronic myelocytic leukemia, colorectal cancer, cutaneous T-cell lymphoma, endometrial cancer, esophageal cancer, Ewing's sarcoma, gallbladder cancer, hairy cell leukemia, head & neck cancer, Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer, liver cancer, lung cancer (small and/or non-small cell), malignant peritoneal effusion, malignant pleural effusion, melanoma, mesothelioma, multiple myeloma, neuroblastoma, non-Hodgkin's lymphoma, osteosarcoma, ovarian cancer, ovary (germ cell) cancer, prostate cancer, pancreatic cancer, penile cancer, retinoblastoma, skin cancer, soft-tissue sarcoma, squamous cell carcinomas, stomach cancer, testicular cancer, thyroid cancer, trophoblastic neoplasms, uterine cancer, vaginal cancer, cancer of the vulva and Wilm's tumor.

### Claim 128 (depends on 126)

The method of claim 126, wherein the compound is selected from the group consisting of:
128

### Claim 129 (depends on 128)

The method of claim 128, wherein the compound is
129

### Claim 130

A method for increasing or extending the lifespan or proliferative capacity of cells or altering the gene expression of senescent cells comprising administering an effective amount of a compound of formula I:
130
or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:
Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, carbocyclic or heterocyclic ring, wherein Y and any heteroatom(s) therein is unsubstituted or independently substituted with at least one non-interfering hydroxy, amino, nitro, dimethylamino, alkylamino, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl substituent;
R1 and R3 are independently hydrogen, alkyl, halo, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, —COOR5 or a moiety selected from the group consisting of:
131
wherein R7 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R2, when present, is hydrogen, alkyl, alkenyl, amino, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R4, R5 and R6 are independently hydrogen, hydroxy, amino, dimethylamino, alkylamino, nitro, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
wherein R2, R4, R5 and R6 are unsubstituted or independently substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkoxy, phenoxy, benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, dimethylamino, alkylamino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, alkylthio, sulfhydryl, halo, haloalkyl, ttifluoromethyl and aryl.

### Claim 131 (depends on 130)

The method of claim 130, wherein the compound is selected from the group consisting of:
132

### Claim 132 (depends on 131)

The method of claim 131, wherein the compound is
133

### Claim 133

A process of making the compound of formula I:
134
or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein:
Y represents the atoms necessary to form a fused 5- to 6-membered, aromatic or non-aromatic, carbocyclic or heterocyclic ring, wherein Y and any heteroatom(s) therein is unsubstituted or independently substituted with at least one non-interfering hydroxy, amino, nitro, dimethylamino, alkylamino, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl substituent;
R1 and R3 are independently hydrogen, alkyl, halo, alkenyl, cycloalkyl, cycloalkenyl, aralkyl, aryl, double bonded oxygen, —COOR5, or a moiety selected from the group consisting of:
135
wherein R7 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R2, when present, is hydrogen, alkyl, alkenyl, amino, cycloalkyl, cycloalkenyl, aralkyl or aryl;
R4, R5 and R6 are independently hydrogen, hydroxy, amino, dimethylamino, alkylamino, nitro, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl;
wherein R2, R4, R5 and R6 are unsubstituted or independently substituted with a moiety selected from the group consisting of alkyl, alkenyl, alkoxy, phenoxy, benzyloxy, cycloalkyl, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, dimethylamino, alkylamino, amido, cyano, isocyano, nitro, nitroso, nitrilo, isonitrilo, imino, azo, diazo, sulfonyl, sulfoxy, thio, thiocarbonyl, alkylthio, sulfhydryl, halo, haloalkyl, trifluoromethyl and aryl;
comprising the step of contacting an intermediate of formula II:
136
with NH2R2.

### Claim 134

The compounds, compositions, methods and processes described herein.
